/BPTH

BPTH Stock - Bio-Path Holdings, Inc.

Q: What is the analyst price target for BPTH?

Analyst price target information is not currently available for BPTH.

Q: What is BPTH's market cap?

Market capitalization information is not currently available for BPTH.

Healthcare|Biotechnology|OTC

$0.07+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.08

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BPTH

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.18

52W High$1.46

52W Low$0.05

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-159,000	$-178,000	$-178,000	$-161,000	$-151,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-11,992,000	$-15,843,000	$-13,901,000	$-10,443,000	$-10,908,000
Net Income	$-9,894,000	$-16,078,000	$-13,835,000	$-10,437,000	$-10,856,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-4.12	$-33.64	$-38.03	$-31.04	$-56.44

Company Overview

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Visit Website

Earnings History & Surprises

BPTH

Beat Rate

44%

Last 18 quarters

Avg Surprise

-108.7%

EPS vs Estimate

Beats / Misses

8/10

Last 12 quarters

Latest EPS

$-0.55

Q3 2025

EPS Surprise History

Q4 23

+5.9%

$-6.40vs$-6.80

Q1 24

-30.6%

$-7.05vs$-5.40

Q2 24

-7.5%

$-4.88vs$-4.54

Q3 24

+24.7%

$-1.16vs$-1.54

Q4 24

+14.7%

$-0.87vs$-1.02

Q1 25

+81.1%

$-0.07vs$-0.37

Q2 25

-5.3%

$-0.40vs$-0.38

Q3 25

-37.5%

$-0.55vs$-0.40

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 13, 2026	—	—	—	—
Q4 2025	Nov 13, 2025	—	—	—	—
Q3 2025	Aug 14, 2025	$-0.40	$-0.55	-37.5%	✗ MISS
Q2 2025	May 15, 2025	$-0.38	$-0.40	-5.3%	✗ MISS
Q1 2025	Mar 27, 2025	$-0.37	$-0.07	+81.1%	✓ BEAT
Q4 2024	Nov 14, 2024	$-1.02	$-0.87	+14.7%	✓ BEAT
Q3 2024	Aug 15, 2024	$-1.54	$-1.16	+24.7%	✓ BEAT
Q2 2024	May 15, 2024	$-4.54	$-4.88	-7.5%	✗ MISS
Q1 2024	Mar 8, 2024	$-5.40	$-7.05	-30.6%	✗ MISS
Q4 2023	Nov 15, 2023	$-6.80	$-6.40	+5.9%	✓ BEAT
Q3 2023	Aug 15, 2023	$-10.40	$-10.60	-1.9%	✗ MISS
Q1 2023	Mar 31, 2023	$-9.00	$-10.60	-17.8%	✗ MISS
Q1 2023	Mar 23, 2023	$-0.46	$-9.51	-1966.8%	✗ MISS
Q4 2022	Nov 15, 2022	$-9.20	$-9.80	-6.5%	✗ MISS
Q3 2022	Aug 15, 2022	$-10.00	$-8.40	+16.0%	✓ BEAT
Q2 2022	May 16, 2022	$-9.20	$-9.40	-2.2%	✗ MISS
Q1 2022	Mar 11, 2022	$-6.40	$-11.80	-84.4%	✗ MISS
Q4 2021	Nov 10, 2021	$-6.60	$-5.80	+12.1%	✓ BEAT
Q3 2021	Aug 13, 2021	$-8.00	$-5.20	+35.0%	✓ BEAT
Q2 2021	May 14, 2021	$-10.00	$-8.60	+14.0%	✓ BEAT